



TSX-V: QPT

## A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life

Quest has 5 independent business units under its umbrella

- Each brings unique technologies to enhance shareholder value
- Operating under their own management, clinical team and Board

Major Focus on the treatment of cancer

- OncoQuest - Antibody Based Combination Immunotherapy
- AmrutBio - Targeted Cancer Therapy
- OncoVent - China Joint Venture for Immunotherapy

Other individual business units bring revenue with development, distribution and sales of consumer health products

- Madenco Biosciences – Cosmetics and consumer health products
- Bioceltran – Transdermal Delivery (PTD) Technology and Photodynamic Therapy Technology

TSX-Venture Exchange Listed	Symbol: QPT
Year Founded	1996
Year Listed	1999
Share Capital	\$35 M
Licensing Fees to Date	\$ 9.6 M
Shares Outstanding	150 M
Warrants Outstanding	20 M
Shareholder Base	South Korea 42% Canada 25% China 17% US 3% Europe 7 % Insiders 6%

### Recent News

#### Dec 07, 2016

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

#### Nov 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

#### Nov 02, 2016






OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

#### Oct 28, 2016

Quest PharmaTech Inc. Announces Change of Auditor

#### Oct 20, 2016

Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

	Cancer Therapies			Consumer Products	
					
Highlights	Three different combinatorial clinical trial are underway for the treatment of ovarian cancer with oregovomab  Her2/neu IgE preclinical development for metastatic breast cancer	Anti-MUC1 MAB AR 20.5 for pancreatic cancer development in China	Novel target (truncated MUC-16) development in collaboration with UNMC	Bellus Skin Serum Cosmetic Product launched in 2016	New Cosmetic Products Development  Cosmetic Hair Removal Clinical Trial with new formulation
Quest ownership information	50%	11%	100%	80%	20%

### Why Quest PharmaTech?

- Unique Business Model with five Strategic Business Units
- Multiple Products in the Clinic
- Diversified Product Pipeline
- Well Financed to meet Milestones
- Creating shareholder value with unique therapies and technologies
- Potential Revenue Generation with Consumer Products Sales
- Experienced management team
- Global network of collaborators and Investors (US, Korea, Europe and China)
- Extensive patent portfolio
- Considerable scientific and clinical publications in peer reviewed journals



TSX-V: QPT

### Quest Scientific Advisory Board Members

**Dr. Chris Nicodemus (Chair)**  
President & CSO, AIT Strategies, US

**Dr. Michael A Hollingsworth, Ph.D.**  
Professor, Eppley Institute, University of Nebraska Medical Center, US

**Dr. Eric Shi, Ph.D.**  
Professor, Nanjing Medical University & Associate Dean, Academy of Clinical & Translational Research, Jiangsu Province

**Dr. Ki-Jun Hwang, Ph.D.**  
Director of Centre for Research in Bioactive Materials, Chonbuk National University, Korea

**Dr. Ronald Moore, M.D., Ph.D., FRCSC**  
Cross Cancer Institute, University of Alberta Hospital, Edmonton, Canada

### OFFICERS AND DIRECTORS

**Dr. Madi R. Madiyalakan, Ph.D.**  
CEO and Director

**Mr. Lorne Meikle, B.A**  
Chairman, Director

**Dr. Eris Shi, Ph.D.**  
Director

**Mr. Ian McConnan, F.C.A.**  
Director

**Mr. Shawn Lu, CIM, M. Finan.**  
Director

**Mr. Pierre Vermette, C.A.**  
Chief Financial Officer

### CONTACT INFORMATION

**Dr. Madi R. Madiyalakan, CEO**  
(780) 448-1400 ext.204  
madi@questpharmatech.com

## A Biotechnology Company Developing and Commercializing Products to Improve Quality of Life



- developing next generation of combinatorial immunotherapy products for the treatment of cancer
- Positive interim results from Phase II clinical study of lead product (oregovomab) with excellent safety profile provides path to a product registration trial
- Initiated antibody manufacturing program to support planned registration trial and commercial use.
- Diversified product pipeline covering almost all cancers that kill, and a novel product class that may qualify for breakthrough designation (IgE). Potential optimization in combination with chemotherapy, immuno-stimulants and checkpoint inhibition
- A China based global pharmaceutical company as major investor and development partner, Hepalink USA



- Joint Venture with Shenzhen Hepalink Pharmaceutical Co., Ltd
- Focus on development of combination immunotherapy for the China market
- Initiated anti-MUC1 MAb AR20.5 manufacturing for Phase II study in pancreatic cancer
- Leverage additional resources to accelerate worldwide Antibody Manufacturing and Clinical Development Strategy

### AmrutBio

- Novel approach for targeted cancer therapy using a combinatorial approach for optimal efficacy
- Lead product (MAb AR9.6) under development is for a novel target (MUC 16) for cancer therapy discovered at University of Nebraska Medical Center
- Second product (ACP2127) under development is a multi-functional inhibitor combining the effect of CDK and mTOR inhibition



- Focused on commercializing scientifically validated consumer health products through development, licensing and acquisition
- Product categories include cosmetics, natural health products and Rx Pharma
- Products based on proprietary transdermal delivery technology licensed from Bioceltran (SP Technology)
- Global Distribution (ex-Korea)- Rights to Bellus Skin Cosmetics



- Quest owns Photodynamic Therapy Technology and Bioceltran owns Protein Transduction Domain (PTD) Technology
- Quest and Bioceltran are developing skin penetrating active molecules for cosmetic and pharmaceutical use
- Quest has worldwide (excluding South Korea) rights to Bioceltran PTD Technology and Products for certain indications
- Bioceltran has exclusive license to Quest's Photodynamic Therapy Technology